Sp911

THE OBESITY EPIDEMIC: A CALL TO ACTION FOR GASTROENTEROLOGY TRAINING

Date
May 8, 2023
Explore related products in the following collection:

Society: AGA

This session, designed for the fellows, clinician educator and program director focuses on designing and delivering curricula for GI fellows on the topics of nutrition, including the obesity epidemic. After a review of the current state and vision or the future, three clinician educators and nutrition experts will highlight resources and approaches to address this vital topics that most training programs struggle to cover. Unique to this session will be the collaboration with a dietician to discuss an approach for interprofessional training in GI using, a core component of ACGME program requirements.

Tracks

Related Products

Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
This session, designed for the fellows, clinician educator and program director focuses on designing and delivering curricula for GI fellows on the topics of nutrition, including the obesity epidemic…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA
Thumbnail for HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…